

Enabling 21st Century Cancer
Research:
Experience from the Cancer
Community

H. Kim Lyerly, MD
Duke Comprehensive Cancer
Institute

caBIG at Duke

- Developer
 - Cancer Central Participant Registry (C3PR)
 - caTRIP
 - Many elements part of other caBIG applications
 - RProteomics
 - VCDE Mentorship
 - CTMS Knowledge Center

caBIG at Duke

- Adopter
 - Flagship C3D implementation
 - Many trials in production, many more in development
 - C3PR multi-center pilot
 - caAERS (CALGB and Duke) (in progress)
 - caGRID
 - caArray (in progress)

Impact of caBIG at Duke


- Investment strategy and long term IT planning aligned with caBIG goals
- Enabling novel clinical trials between cancer centers
- Enabling biomarker intense (real time gene array based) clinical trials
- Improving access and services to underserved populations

A randomized phase II trial

A) DC infected with rV-CEA(6D)-TRICOM followed by DC infected with rF-CEA(6D)-TRICOM

versus

B) rV-CEA(6D)-TRICOM followed by rF-CEA(6D)-TRICOM along with in situ GM-CSF following hepatic metastasis resection and adjuvant chemotherapy.



**Manufacturing
and QA/QC of
vaccine, analysis
of immune
response**

**Portland Medical
Center**

**Duke University
Medical Center**

**Moffitt Cancer
Center**

**Collection of cells,
distribution of vaccine,
collection of data**


**Medical
University of
South Carolina**

MD Anderson

Georgetown

**Wake
Forest/Bowman
Gray**


Clinical Trial Software Elements



Lung Cancer Prognostic Markers




The NEW ENGLAND
JOURNAL of MEDICINE



A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer



Anil Potti, M.D., Sayan Mukherjee, Ph.D.,
Rebecca Petersen, M.D., Holly K. Dressman,
Ph.D., Andrea Bild, Ph.D., Jason Koontz, M.D.,
Robert Kratzke, M.D., Mark A. Watson, M.D.,
Ph.D., Michael Kelley, M.D., Geoffrey S.
Ginsburg, M.D., Ph.D., Mike West, Ph.D., David
H. Harpole, Jr., M.D., and Joseph R. Nevins,
Ph.D.



Predictive Markers-Chemotherapy




Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Gray, J., Marks, J., Kelley, M., Berchuck, A., Petersen, R., Harpole, D., Ginsburg, G. S., Febbo, P., Lancaster, J. M., and Nevins, J. R. (2006). A genomic strategy to guide the use of chemotherapeutic drugs in solid tumors. Nat. Med. 12, 1294-1300.

BOP0701 – A Randomized Phase II Study to Evaluate the Capacity of Expression Signatures to Guide Neoadjuvant Breast Cancer Chemotherapy (DOD Breast Program)




Can gene expression profiling demonstrate an activated pathway, suggesting that inhibition would predict response to a therapy?

Phase II Studies to Evaluate a Src Pathway Signature as a Predictor of Dasatinib Response



Nature 439, 353-357.

**Peking
University/Beijing
Cancer Hospital**



**Gene expression
analysis and
generation of
gene signature**

**Collection of tumors,
collection of data**

**Duke University
Medical Center**


**Duke
Health
Raleigh**

**Non-Duke
Clinics**




Patient-controlled Exchange of Breast Imaging Studies to Healthcare Providers

- **web-based system**
- **allows patients to access, download and transfer the DICOM files of all their imaging studies.**
- **makes them usable by medical care providers or researchers at any other medical center.**
- **improve health care**
- **reduce radiation dose from unnecessary duplicate imaging studies**
- **facilitate a wide array of research that requires data from images**



Technical Architecture for Image Transfer



Potential caBIG solutions

- Technical challenges can be addressed
- Standards for community providers from NCI
- Can address other issues that may have limited implementation of previous strategies:
 - HIPAA (HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996)
 - Reporting concordant/non-concordant results (quality)
 - Billing
 - Liability